Loading patent…
AssigneeUniversity of South Florida
InventorsSubhra Mohapatra, Shyam S. Mohapatra, Ryan Green, Karthick Mayilsamy
Estimating the term…
Glioblastoma is an extremely rare form of brain cancer that has a very low survival rate. Cannabinoid compounds such as cannabidiol (CBD) have been shown to have anti-cancer effects in glioblastoma, which can synergize with glioblastoma therapeutics such as temozolomide (TMZ). However, mono- or combination therapies of CBD can inadvertently activate resistance mechanisms, such as through increased expression or activation of the C-C motif chemokine ligand 20 (CCL20) and its receptor (CCR6) axis. Furthermore, while CBD has been shown to synergize with TMZ to enhance potency against glioblastoma, the heterogeneity of glioblastoma within tumors and amongst patients is challenging to treat, necessitating more personalized combination therapies. Disclosed herein are compositions and methods for treating cannabidiol (CBD)- and/or temozolomide (TMZ)-refractory glioblastoma.
A composition for treating CBD- and/or TMZ-refractory glioblastoma, comprising a cannabinoid, temozolomide (TMZ), a CCL20/CCR6 inhibitor, or a pharmaceutically acceptable salt thereof.
A method of treating CBD- and/or TMZ-refractory glioblastoma, comprising administering a therapeutically effective amount of a cannabinoid, TMZ, a CCL20/CCR6 inhibitor, or pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.